Frost & Sullivan Predicts Growth for the Infectious Disease Diagnostics Market

Frost & Sullivan Predicts Growth for the Infectious Disease Diagnostics Market PR Newswire LONDON, Sept. 26, 2012 - Point-of-care and molecular testing will be the highest growth segments in the infectious disease testing market LONDON, Sept. 26, 2012 /PRNewswire/ -- The infectious disease diagnostics market is driven by unprecedented outbreaks of infections and rising awareness of people and policy makers toward the vital use of diagnostic tools to control widespread outbreaks. In developed markets, infectious disease testing is moving toward the patients' bedside and the physicians' office laboratories (POL). This is expected to be a growing trend, where the first round of testing will be done in the POL and samples will be sent to the central laboratories for confirmatory testing alone. New analysis from Frost & Sullivan, Western European Infectious Disease Testing Market, (www.drugdiscovery.frost.com), finds that the market earned revenues of $74.1 million for MRSA segment, $13.2 million for TB segment, $42.1 million for HPV segment and $3.9 million for hantavirus infections in 2011. "The point-of-care and molecular testing segments are the highest growth segments in the infectious disease testing market," notes Frost & Sullivan Research Analyst Tridisha Goswami.